Vimarsana
Biggest News Aggregation in the World

Niklas Worm Andersson News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Niklas Worm Andersson. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Niklas Worm Andersson Today - Breaking & Trending Today

Thiazide Diuretics May Promote Hyponatremia - Vimarsana News

Thiazide Diuretics May Promote Hyponatremia

The risk for hyponatremia was higher with thiazide drugs compared with nonthiazide drugs in older adults and patients with comorbidities.

LDL-Lowering Tied to Lower First CVD Events in Patients 70+ - Vimarsana News

LDL-Lowering Tied to Lower First CVD Events in Patients 70+

People 70 years of age and older taking LDL cholesterol-lowering therapy for primary prevention have the same reduction in major vascular events as their younger counterparts, new research confirms.

Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study - Vimarsana News

Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study

Objective To estimate the effectiveness of the bivalent mRNA booster vaccines containing the original SARS-CoV-2 and omicron BA.4-5 or BA.1 subvariants as the fourth dose against severe covid-19. Design Nationwide cohort analyses, using target trial emulation. Setting Denmark, Finland, Norway, and Sweden, from 1 July 2022 to 10 April 2023. Participants People aged ≥50 years who had received at least three doses of covid-19 vaccine (that is, a primary course and a first booster). Main outcome measures The Kaplan-Meier estimator was used to compare the risk of hospital admission and death rela...

Source: bmj.com
Safety of BA.4-5 or BA.1 bivalent mRNA booster vaccines: nationwide cohort study - Vimarsana News

Safety of BA.4-5 or BA.1 bivalent mRNA booster vaccines: nationwide cohort study

Objective To examine the association between the omicron adapted bivalent mRNA covid-19 booster vaccines received as a fourth dose and risk of adverse events. Design Nationwide cohort study. Setting Denmark. Participants 2 225 567 adults aged ≥50 years who received three covid-19 vaccine doses during the study period, 1 January 2021 to 10 December 2022. Main outcome measures The main outcome measure was rates of hospital visits for 27 different adverse events in a 28 day main risk period after vaccination with a bivalent omicron adapted mRNA booster vaccine as a fourth dose compared with...

Source: bmj.com
Comparative effectiveness of heterologous third dose vaccine schedules against severe covid-19 during omicron predominance in Nordic countries: population based cohort analyses - Vimarsana News

Comparative effectiveness of heterologous third dose vaccine schedules against severe covid-19 during omicron predominance in Nordic countries: population based cohort analyses

Objective To investigate the comparative vaccine effectiveness of heterologous booster schedules (ie, three vaccine doses) compared with primary schedules (two vaccine doses) and with homologous mRNA vaccine booster schedules (three vaccine doses) during a period of omicron predominance. Design Population based cohort analyses. Setting Denmark, Finland, Norway, and Sweden, 27 December 2020 to 31 December 2022. Participants All adults aged ≥18 years who had received at least a primary vaccination schedule of AZD1222 (Oxford-AstraZeneca) or monovalent SARS-CoV-2 wild type (ancestral) strain ba...

Source: bmj.com